glp-1 that starts with r 30mg (Research Only) 𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿

Most patients experience significant weight regain after stopping GLP-1 medications, with clinical trials showing regain of substantial weight within the first year

Clinicians should counsel patients about reliable contraception during therapy and appropriate drug discontinuation timelines

The FDA approved GLP-1s after testing them in large clinical trials (such as STEP and SURMOUNT ) at specific doses and intervals

However, the risk increases if you are also taking insulin or a sulfonylurea (such as gliclazide)

Covered drugs in this tier include Ozempic, Mounjaro, Victoza, Trulicity, and Bydureon

When to talk to your provider If you have reached the maximum recommended dose and maintained it for 12 to 16 weeks without achieving at least 5% body weight loss, a conversation with your provider is warranted